Results 251 to 260 of about 31,391,825 (411)

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

Molecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He, Chiara Testini, Neda Hekmati, Altea Bonello, Aglaia Schiza, Emmanuel Nwadozi, Mia Phillipson, Carina Strell, Michael Welsh   +8 more
wiley   +1 more source

Implementing an Interprofessional Simulation Program for Paediatric Patient Safety. [PDF]

Clin Teach
D'Arienzo D, Dandavino M, Matte AA, Welsh S, Rich C, Korah N.   +5 more
europepmc   +1 more source

Patient measures for respiratory patients [PDF]

Chronic Respiratory Disease, 2018
openaire   +2 more sources

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

The Longevity Medicine Patient Experience Framework: A Seven-Domain Model for Optimizing Person-Centered Longevity Medicine. [PDF]

J Patient Exp
Osório TG, Robertson-Malt S, McGrath R, Qureshi N, Lee-St John T, Cassidy L, Pena-Acuna V, Buckley L, Piechowski-Jozwiak B, Sirotin N.   +9 more
europepmc   +1 more source

Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists [PDF]

, 2019
Dimitrios Patoulias, Maria‐Styliani Kalogirou, Konstantinos Stavropoulos, Κonstantinos Imprialos, Michael Doumas   +4 more
openalex   +1 more source

Measuring Patient Satisfaction Changes Patient Satisfaction

Journal of Dermatological Treatment, 2012
Candace, Glenn, Amy, McMichael, Steven R, Feldman   +2 more
openaire   +3 more sources

Patient Satisfaction after Total Knee Arthroplasty: Who is Satisfied and Who is Not?

Clinical Orthopaedics and Related Research, 2010
R. Bourne, B. Chesworth, A. Davis, N. Mahomed, K. Charron   +4 more
semanticscholar   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source